BOSTON SCIENTIFIC CORP
BSXAPI behind this page
BSX Q1 2026 request
Playground key active
/api/financials?ticker=BSX&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 5,203 | 4,663 | +11.6% |
Show Product Lines breakouts |
|||
| Cardiac Rhythm Management | 578 | 578 | 0.0% |
| Cardiac Rhythm Management · Non Us | 229 | 220 | +4.1% |
| Cardiac Rhythm Management · US | 349 | 358 | -2.5% |
| Electrophysiology | 905 | 730 | +24.0% |
| Electrophysiology · Non Us | 302 | 219 | +37.9% |
| Electrophysiology · US | 603 | 511 | +18.0% |
| Endoscopy | 736 | 673 | +9.4% |
| Endoscopy · Non Us | 290 | 253 | +14.6% |
| Endoscopy · US | 446 | 420 | +6.2% |
| Interventional Cardiology & Vascular Therapies | 1,244 | 1,124 | +10.7% |
| Interventional Cardiology & Vascular Therapies · Non Us | 692 | 657 | +5.3% |
| Interventional Cardiology & Vascular Therapies · US | 552 | 467 | +18.2% |
| Interventional Oncology & Embolization | 268 | 228 | +17.5% |
| Interventional Oncology & Embolization · Non Us | 99 | 87 | +13.8% |
| Interventional Oncology & Embolization · US | 170 | 142 | +19.7% |
| Neuromodulation | 318 | 271 | +17.3% |
| Neuromodulation · Non Us | 82 | 67 | +22.4% |
| Neuromodulation · US | 236 | 204 | +15.7% |
| Urology | 646 | 633 | +2.1% |
| Urology · Non Us | 182 | 165 | +10.3% |
| Urology · US | 465 | 469 | -0.9% |
| Watchman | 506 | 425 | +19.1% |
| Watchman · Non Us | 44 | 34 | +29.4% |
| Watchman · US | 462 | 390 | +18.5% |
Show Business Segments breakouts |
|||
| BSX Reportable Segments [Member] · Asia Pacific | 803 | 701 | +14.6% |
| BSX Reportable Segments [Member] · EMEA | 932 | 846 | +10.2% |
| BSX Reportable Segments [Member] · Latin America and Canada | 185 | 155 | +19.4% |
| Cardiovascular | 3,503 | 3,085 | +13.5% |
| Cardiovascular · Non Us | 1,366 | 1,218 | +12.2% |
| Cardiovascular · US | 2,137 | 1,868 | +14.4% |
| MedSurg | 1,701 | 1,577 | +7.9% |
| MedSurg · Non Us | 554 | 484 | +14.5% |
| MedSurg · US | 1,147 | 1,093 | +4.9% |
Show Geography breakouts |
|||
| Non Us | 1,920 | 1,702 | +12.8% |
| US | 3,284 | 2,960 | +10.9% |
| Cost of Revenue | 1,590 | 1,453 | +9.4% |
| Gross Profit | 3,614 | 3,210 | +12.6% |
| Selling, General & Administrative | 1,781 | 1,597 | +11.5% |
| Research And Development Expense Excluding Acquired In Process Cost | 516 | 443 | +16.5% |
| Royalty Expense | 12 | 14 | -14.3% |
| Amortization Of Intangible Assets | 232 | 219 | +5.9% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -30 | 5 | -700.0% |
| Restructuring Charges | 3 | 10 | -70.0% |
| Operating Expenses | 2,513 | 2,288 | +9.8% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 199 | 255 | -22.0% |
| Operating Income | 1,101 | 921 | +19.5% |
| Interest Expense | -90 | -82 | -9.8% |
| Other Nonoperating Income Expense Net | 151 | -34 | +544.1% |
| Income Before Taxes | 1,162 | 805 | +44.3% |
| Income Tax Expense (Benefit) | -176 | 133 | -232.3% |
| Net Income | 1,339 | 672 | +99.3% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,339 | 672 | +99.3% |
| Net Income Loss Attributable To Noncontrolling Interest | -2 | -2 | 0.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | -2 | -2 | 0.0% |
| Retained Earnings | 2 | 2 | 0.0% |
| Net Income Loss Available To Common Stockholders Basic | 1,341 | 674 | +99.0% |
| EPS (Basic) | 0.9 | 0.46 | +95.7% |
| EPS (Diluted) | 0.9 | 0.45 | +100.0% |
| Wtd Avg Shares (Basic) | 1,484.9 | 1,477.2 | +0.5% |
| Wtd Avg Shares (Diluted) | 1,495 | 1,493.1 | +0.1% |
| Other Non-Operating Income (Expense) | 61 | -116 | +152.6% |
| Comprehensive Income | 1,552 | 372 | +317.2% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Designated As Hedging Instrument | 76 | -55 | +238.2% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Hedging Designation breakouts |
|||
| Nondesignated · Other Nonoperating Income Expense | -21 | 42 | -150.0% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,453 | 725 | +100.4% |
| Accounts Notes And Loans Receivable Net Current | 3,027 | 2,693 | +12.4% |
| Inventory | 3,117 | 2,867 | +8.7% |
| Prepaid Taxes | 358 | 294 | +21.8% |
| Prepaid Expenses & Other Current Assets | 729 | 756 | -3.6% |
| Total Current Assets | 8,684 | 7,335 | +18.4% |
| Non-Current Assets | |||
| Goodwill | 18,536 | 17,340 | +6.9% |
Show Business Segments breakouts |
|||
| Cardiovascular | 10,560 | 9,841 | +7.3% |
| MedSurg | 7,977 | 7,500 | +6.4% |
| Deferred Tax Assets | 3,953 | 3,676 | +7.5% |
| Other Non-Current Assets | 2,054 | — | — |
| Total Assets | 44,351 | 40,140 | +10.5% |
| Property, Plant & Equipment | 4,063 | — | — |
| Operating Lease Right-of-Use Assets | 547 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 4,063 | — | — |
| Intangible Assets Net Excluding Goodwill | 7,060 | 6,566 | +7.5% |
| Current Liabilities | |||
| Debt Current | 41 | — | — |
| Accounts Payable | 1,141 | 1,004 | +13.6% |
| Accrued Liabilities | 2,514 | — | — |
| Other Liabilities Current | 875 | — | — |
| Total Current Liabilities | 4,571 | 5,058 | -9.6% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 219 | 158 | +38.6% |
| Other Non-Current Liabilities | 2,469 | — | — |
| Long-Term Debt (Q) | — | — | — |
Show Long-Term Debt Type breakouts |
|||
| December 2027 Notes | 900 | 900 | 0.0% |
| Financial Lease Obligation | 124 | — | — |
| January 2040 Notes | 300 | 300 | 0.0% |
| June 2030 Notes | 1,200 | 1,200 | 0.0% |
| March 2028 Notes | 344 | 344 | 0.0% |
| March 2028 Senior Notes | 864 | 811 | +6.5% |
| March 2029 Euro Senior Notes | 864 | 811 | +6.5% |
| March 2029 Notes | 272 | 272 | 0.0% |
| March 2031 Notes | 864 | 811 | +6.5% |
| March 2031 Notes 2 | 979 | 919 | +6.5% |
| March 2032 Euro Senior Notes | 1,439 | 1,352 | +6.4% |
| March 2034 Notes | 576 | 541 | +6.5% |
| March 2034 Notes 2 | 748 | 703 | +6.4% |
| March 2039 Notes | 450 | 450 | 0.0% |
| March 2049 Notes | 650 | 650 | 0.0% |
| November 2035 Notes | 350 | 350 | 0.0% |
| Senior Notes | 10.94 | 11.24 | -2.7% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 10,988 | 10,532 | +4.3% |
| Stockholders' Equity | |||
| Common Stock | 17 | 17 | 0.0% |
| Treasury Stock Value | -2,251 | -2,251 | 0.0% |
| Additional Paid In Capital Common Stock | 21,584 | 21,127 | +2.2% |
| Retained Earnings | 6,912 | 3,347 | +106.5% |
| Accumulated Other Comprehensive Income | -398 | -28 | -1321.4% |
| Total Stockholders' Equity | 25,864 | 22,212 | +16.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1 | -17 | +94.1% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 31 | 69 | -55.1% |
| Accumulated Other Comprehensive Income | -399 | -28 | -1325.0% |
| Accumulated Translation Adjustment | -428 | -80 | -435.0% |
| Minority Interest | 240 | 233 | +3.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 26,104 | 22,446 | +16.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -398 | -28 | -1321.4% |
| Additional Paid In Capital | 21,584 | 21,127 | +2.2% |
| Common Stock | 17 | 17 | 0.0% |
| Noncontrolling Interest | 240 | 233 | +3.0% |
| Parent | 25,864 | 22,212 | +16.4% |
| Retained Earnings | 6,912 | 3,347 | +106.5% |
| Treasury Stock Common | -2,251 | -2,251 | 0.0% |
| Total Liabilities & Equity | 44,351 | 40,140 | +10.5% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 351 | 325 | +8.0% |
| Cash Flow Impact Of Deferred Income Tax Expense Benefit | -351 | 41 | -956.1% |
| Stock-Based Compensation | 83 | 74 | +12.2% |
| Gain Loss On Investments | -158 | 28 | -664.3% |
| Inventory Step Up Amortization | 2 | 81 | -97.5% |
| Other Operating Activities Cash Flow Statement | 27 | -7 | +485.7% |
| Change in Accounts Receivable | -117 | -107 | -9.3% |
| Change in Inventory | -177 | -109 | -62.4% |
| Increase Decrease In Other Operating Assets | -109 | -77 | -41.6% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -512 | -385 | -33.0% |
| Net Cash from Operations | 348 | 541 | -35.7% |
| Investing Activities | |||
| Capital Expenditures | -177 | -187 | +5.3% |
| Payments To Acquire Businesses Net Of Cash Acquired | -523 | -239 | -118.8% |
| Proceeds From Payments For Investments And Acquisitions Of Certain Technologies | 61 | -77 | +179.2% |
| Other Investing Activities | 48 | 3 | +1500.0% |
| Net Cash from Investing | -591 | -500 | -18.2% |
| Financing Activities | |||
| Finance Lease Principal Payments | 0 | -36 | +100.0% |
| Repayments Of Short Term Debt | -259 | -1,083 | +76.1% |
| Paymenttonetsharesettleemployeeequityawards | -85 | -118 | +28.0% |
| Proceeds From Stock Plans | 81 | 115 | -29.6% |
| Proceeds From Payments For Other Financing Activities | 3 | -10 | +130.0% |
| Net Cash from Financing | -260 | 233 | -211.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 0 | 39 | -100.0% |
| Net Change in Cash | -504 | 314 | -260.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,643 | 919 | +78.8% |
| Restricted Cash And Cash Equivalents At Carrying Value | 71 | 103 | -31.1% |
| Restricted Cash Equivalents Noncurrent | 119 | 91 | +30.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.